Back to Search Start Over

Clonal evolution as detected by interphase fluorescence in situ hybridization is associated with worse overall survival in a population-based analysis of patients with chronic lymphocytic leukemia in British Columbia, Canada.

Authors :
Huang SJ
Bergin K
Smith AC
Gerrie AS
Bruyere H
Dalal CB
Sugioka DK
Hrynchak M
Ramadan KM
Karsan A
Gillan TL
Toze CL
Source :
Cancer genetics [Cancer Genet] 2017 Jan; Vol. 210, pp. 1-8. Date of Electronic Publication: 2016 Nov 03.
Publication Year :
2017

Abstract

This study evaluates prognostic markers as predictors of clonal evolution (CE) and assesses the impact of CE on overall survival (OS) in a population-based cohort of 159 consecutive eligible patients with chronic lymphocytic leukemia (CLL) obtained from the British Columbia Provincial CLL Database. CE was detected by interphase fluorescence in situ hybridization (FISH) in 34/159 patients (21%) with 65% of CE patients acquiring deletion 17p or 11q. CD38 positive status (≥30%) on flow cytometry predicted 2.7 times increased risk of high-risk CE (acquisition of deletion 17p or 11q) on multivariate analysis. Prior CLL therapy was not a significant predictor of CE. CE was associated with 4.1 times greater risk of death when analyzed as a time-dependent variable for OS after adjusting for age, lymphocyte count, and FISH timing. High-risk CE was associated with worse OS while acquisition of low/intermediate-risk abnormalities (trisomy 12, deletion 13q, and IGH translocation) had no difference in OS. Our study demonstrates the negative impact of CE detected by FISH on OS in this population-based cohort. These data provide support for repeating FISH testing during CLL follow-up as patients with high-risk CE have reduced survival and may require closer observation.<br /> (Copyright © 2016 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
2210-7762
Volume :
210
Database :
MEDLINE
Journal :
Cancer genetics
Publication Type :
Academic Journal
Accession number :
28212806
Full Text :
https://doi.org/10.1016/j.cancergen.2016.10.006